Efficacy and safety of open‐label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study

BACKGROUND: Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life‐threatening autoimmune thrombotic microangiopathy. Caplacizumab, an anti‐von Willebrand Factor Nanobody(®), is effective for treating aTTP episodes and is well tolerated. OBJECTIVES AND METHODS: In the phase 3 HERCULES t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Thromb Haemost
Main Authors: Knoebl, Paul, Cataland, Spero, Peyvandi, Flora, Coppo, Paul, Scully, Marie, Kremer Hovinga, Johanna A., Metjian, Ara, de la Rubia, Javier, Pavenski, Katerina, Minkue Mi Edou, Jessica, De Winter, Hilde, Callewaert, Filip
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
THROMBOSIS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7027866/
https://ncbi.nlm.nih.gov/pubmed/31691462
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jth.14679
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados